AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23586801 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol valerate/dienogest (E2V/DNG)
Number of subjects: 0
Study 23586801 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 20496094 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 MDCT scans performed with oral and intravenous contrast
Number of subjects: 303
Study 20496094 — intervention group
Group type: COMPARATOR
Intervention: 64 MDCT scans performed solely with intravenous contrast
Number of subjects: 303
Study 18206918 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride 0.2 mg daily for 12 weeks
Number of subjects: 61
Study 18206918 — intervention group
Group type: COMPARATOR
Intervention: Naftopidil 50 mg daily for 12 weeks
Number of subjects: 61
Study 16401650 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25mg
Number of subjects: 7
Study 16401650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 16401650 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25mg after 2 weeks
Number of subjects: 7
Study 16401650 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 2 weeks
Number of subjects: 7
Study 14556878 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban before primary angioplasty
Number of subjects: 61
Study 14556878 — intervention group
Group type: COMPARATOR
Intervention: Glycoprotein IIb/IIIa inhibitors after initial coronary angiography
Number of subjects: 61
Study 10950233 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (1000 microg daily for 7 days)
Number of subjects: 24
Study 10950233 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluticasone propionate (1000 microg)
Number of subjects: 24
Study 8643221 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 250 mg/m2, followed by L-folinic acid (LFA) 250 mg/m2 and 5-fluorouracil (FU) 600 mg/m2
Number of subjects: 21
Study 8643221 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) 500 mg/m2, followed by L-folinic acid (LFA) 250 mg/m2 and 5-fluorouracil (FU) 600 mg/m2
Number of subjects: 21
Study 1729814 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg/day)
Number of subjects: 10
Study 1729814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6382640 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course chemotherapy for silicotuberculosis
Number of subjects: 94
Study 31707985 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip replacement surgery
Number of subjects: 22
Study 30554423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers with high and medium inhibitory control (IC)
Number of subjects: 181
Study 30554423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers with low inhibitory control (IC)
Number of subjects: 181
Study 30554423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' PTSD symptoms
Number of subjects: 181
Study 30554423 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory control (IC) skills
Number of subjects: 181
Study 30554423 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect effect of trauma exposure on parenting measures through PTSD
Number of subjects: 181
Study 27488474 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-Family Partnership plus existing services
Number of subjects: 1040
Study 27488474 — intervention group
Group type: COMPARATOR
Intervention: Existing services
Number of subjects: 1040
Study 24308845 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognitive theory, theory of planned behaviour, protection motivation theory
Number of subjects: 287
Study 24308845 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report PA
Number of subjects: 287
Study 22677752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of reamberin and cycloferon
Number of subjects: 73
Study 22677752 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 73
Study 19841156 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 5, 10, 15, or 20 mg daily for a minimum of 32 weeks
Number of subjects: 172
Study 18633463 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B Vitality Pro White power toothbrush
Number of subjects: 0
Study 18633463 — intervention group
Group type: COMPARATOR
Intervention: Dental prophylaxis followed by ADA reference manual toothbrush
Number of subjects: 0
Study 16141449 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment
Number of subjects: 547
Study 16141449 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 547
Study 11844946 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized mental stressor
Number of subjects: 15
Study 11844946 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 15
Study 11844946 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 10894434 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 20
Study 10894434 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 20
Study 8803304 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 to 30 mg/day)
Number of subjects: 35
Study 8803304 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (100 to 125 mg/day)
Number of subjects: 35
Study 8803304 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 35
Study 8803304 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 35
Study 1376306 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (bleomycin 10 mg/m2/day, methotrexate 120 mg/m2, folinic acid, 5-fluorouracil 600 mg/m2, cisplatin 120 mg/m2)
Number of subjects: 131
Study 1376306 — intervention group
Group type: COMPARATOR
Intervention: Locoregional treatment alone (control group)
Number of subjects: 131
Study 1376306 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 131
Study 3934685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pindolol (0.0256 mg/kg)
Number of subjects: 6
Study 3934685 — intervention group
Group type: COMPARATOR
Intervention: Submaximal exercise
Number of subjects: 6
Study 30644999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led decentralized ART treatment program
Number of subjects: 800
Study 30644999 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized case management approach
Number of subjects: 800
Study 30644999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nurse-led decentralized ART and individualized case management
Number of subjects: 800
Study 30644999 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 800
Study 29805112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 54
Study 29805112 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 54
Study 29805112 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 54
Study 26974227 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 78
Study 26974227 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin
Number of subjects: 78
Study 26974227 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (fluoroquinolone-resistant organisms)
Number of subjects: 78
Study 26974227 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (susceptible organisms)
Number of subjects: 78
Study 26974227 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (intermediately resistant organisms)
Number of subjects: 78
Study 25328284 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) 80 ppm throughout the operation
Number of subjects: 45
Study 25328284 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at the beginning and end of the operation
Number of subjects: 45
Study 25328284 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrogen, N2) throughout the operation
Number of subjects: 45
Study 22971854 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass
Number of subjects: 12
Study 22971854 — intervention group
Group type: COMPARATOR
Intervention: Control (without bioactive glass)
Number of subjects: 12
Study 20828223 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime administration of amlodipine-olmesartan
Number of subjects: 31
Study 20828223 — intervention group
Group type: COMPARATOR
Intervention: Morning administration of amlodipine-olmesartan
Number of subjects: 31
Study 18405399 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (intervention in the VISTA study)
Number of subjects: 130
Study 15665326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 107
Study 15665326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 12612246 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 16
Study 12612246 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 16
Study 10521860 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol reduction
Number of subjects: 0
Study 10521860 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted normal errors regression and random effects logistic regression
Number of subjects: 0
Study 10521860 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods allowing for an additive component of residual heterogeneity
Number of subjects: 0
Study 10521860 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted maximum likelihood estimator
Number of subjects: 0
Study 10521860 — intervention group
Group type: EXPERIMENTAL
Intervention: Binomial model for observed proportions
Number of subjects: 0
Study 7562763 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physical therapy (weekly sessions)
Number of subjects: 207
Study 7562763 — intervention group
Group type: COMPARATOR
Intervention: Daily exercises at home
Number of subjects: 207
Study 7562763 — intervention group
Group type: EXPERIMENTAL
Intervention: Low impact fitness
Number of subjects: 207
Study 7562763 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 207
Study 7562763 — intervention group
Group type: COMPARATOR
Intervention: Controls (for FM)
Number of subjects: 207
Study 1976580 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of 150 mg of roxatidine and 50 mg of pirenzepine
Number of subjects: 0
Study 1976580 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of roxatidine
Number of subjects: 0
Study 1976580 — intervention group
Group type: COMPARATOR
Intervention: Control placebo group
Number of subjects: 0
Study 7387018 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose theophylline (17 to 22 micrograms/mL)
Number of subjects: 10
Study 7387018 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (9.0 to 12.5 micrograms/mL)
Number of subjects: 10
Study 7387018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31529691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tDCS and WMT
Number of subjects: 201
Study 31529691 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS and WMT
Number of subjects: 201
Study 31529691 — intervention group
Group type: COMPARATOR
Intervention: tDCS and control cognitive training (CCT)
Number of subjects: 201
Study 27746068 — intervention group
Group type: EXPERIMENTAL
Intervention: PPBS monitoring
Number of subjects: 240
Study 27746068 — intervention group
Group type: COMPARATOR
Intervention: FBS monitoring
Number of subjects: 240
Study 25847558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance group
Number of subjects: 46
Study 23963662 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet Self-Reading (LSR)
Number of subjects: 321
Study 23963662 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Instruction (CAI)
Number of subjects: 321
Study 23963662 — intervention group
Group type: COMPARATOR
Intervention: Individual Counseling (combined with LSR or CAI)
Number of subjects: 321
Study 21107937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal infusion of morphine
Number of subjects: 30
Study 19125977 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha System
Number of subjects: 45
Study 19125977 — intervention group
Group type: COMPARATOR
Intervention: ProTaper Universal
Number of subjects: 45
Study 19125977 — intervention group
Group type: COMPARATOR
Intervention: Stainless Steel Hand Instruments
Number of subjects: 45
Study 18042770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ministernotomy (group 2)
Number of subjects: 60
Study 18042770 — intervention group
Group type: COMPARATOR
Intervention: Full sternotomy (group 1)
Number of subjects: 60
Study 15252700 — intervention group
Group type: EXPERIMENTAL
Intervention: Varying the direction of motion (from 0 degrees to 315 degrees in steps of 45 degrees)
Number of subjects: 9
Study 15252700 — intervention group
Group type: EXPERIMENTAL
Intervention: Varying the size of the targets (W: 2.5, 1.25, and 0.625 cm)
Number of subjects: 9
Study 15252700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature of the mapping (linear or non-linear) between effector space and task space
Number of subjects: 9
Study 15252700 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical constraints at the level of the effector
Number of subjects: 9
Study 15252700 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational constraints at the level of the task
Number of subjects: 9
Study 11679925 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-, medium-, or high-dose recombinant gp120 vaccine with MF59 adjuvant
Number of subjects: 61
Study 11679925 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated vaccine schedule (birth and ages 2, 8, and 20 weeks) with defined optimal dose
Number of subjects: 61
Study 11679925 — intervention group
Group type: COMPARATOR
Intervention: Placebo (MF59 alone)
Number of subjects: 61
Study 10209587 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft Cast (semi-rigid cast)
Number of subjects: 57
Study 10209587 — intervention group
Group type: COMPARATOR
Intervention: Scotchcast Plus (rigid cast)
Number of subjects: 57
Study 8135449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate, 1 g every 4 hours
Number of subjects: 244
Study 8135449 — intervention group
Group type: COMPARATOR
Intervention: Antacid (aluminum hydroxide and magnesium hydroxide), 20 mL every 2 hours
Number of subjects: 244
Study 8135449 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg as a continuous intravenous infusion
Number of subjects: 244
Study 8135449 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 244
Study 2644391 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g single dose of metronidazole for male partners
Number of subjects: 0
Study 2644391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2644391 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-day course of 500 mg metronidazole twice a day
Number of subjects: 0
Study 2644391 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose metronidazole
Number of subjects: 0
Study 1261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.1 mg/kg i.v.)
Number of subjects: 10
Study 1261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (0.1 mg/kg i.v.)
Number of subjects: 10
Study 1261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of practolol and verapamil (0.1 mg/kg i.v.)
Number of subjects: 10
Study 1261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of practolol and verapamil (practolol preceding verapamil)
Number of subjects: 10
Study 29761537 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded isometric contraction
Number of subjects: 40
Study 29761537 — intervention group
Group type: COMPARATOR
Intervention: Normal posture
Number of subjects: 40
Study 27899754 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation combined with constraint-induced movement therapy
Number of subjects: 44
Study 27899754 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation combined with constraint-induced movement therapy
Number of subjects: 44
Study 25381458 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 175
Study 25381458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 25381458 — intervention group
Group type: COMPARATOR
Intervention: Other therapies
Number of subjects: 175
Study 25381458 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 175
Study 23642843 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-lateral exposure (DL)
Number of subjects: 72
Study 23642843 — intervention group
Group type: EXPERIMENTAL
Intervention: Antero-lateral exposure (AL)
Number of subjects: 72
Study 23642843 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior exposure (P)
Number of subjects: 72
Study 23642843 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 72
Study 21501814 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive support intervention (school fees, uniforms, community visitor monitoring)
Number of subjects: 105
Study 20415933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole mouthrinse
Number of subjects: 0
Study 20415933 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole mouthpaint
Number of subjects: 0
Study 17724283 — intervention group
Group type: EXPERIMENTAL
Intervention: ZNS 5 mg
Number of subjects: 52
Study 17724283 — intervention group
Group type: EXPERIMENTAL
Intervention: ZNS 10 mg
Number of subjects: 52
Study 17724283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 15134386 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CHS) 800 mg orally plus naproxen 500 mg
Number of subjects: 24
Study 15134386 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg only
Number of subjects: 24
Study 11822472 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (100 mg/day for 5 days)
Number of subjects: 66
Study 11822472 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 days)
Number of subjects: 66
Study 9680769 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% salicylic acid and 10% urea ointment (Kerasal)
Number of subjects: 70
Study 9680769 — intervention group
Group type: COMPARATOR
Intervention: 12% ammonium lactate lotion (Lac‐Hydrin)
Number of subjects: 70
Study 8043891 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg/day)
Number of subjects: 15
Study 8043891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2545366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100 mcg/kg
Number of subjects: 220
Study 2545366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 150 mcg/kg
Number of subjects: 220
Study 2545366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 200 mcg/kg
Number of subjects: 220
Study 2545366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 30601345 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message appointment reminder
Number of subjects: 123
Study 30601345 — intervention group
Group type: COMPARATOR
Intervention: Standard scheduling with no reminder
Number of subjects: 123
Study 29629778 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate coaching
Number of subjects: 89
Study 29629778 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 89
Study 28371872 — intervention group
Group type: EXPERIMENTAL
Intervention: Rainy season
Number of subjects: 501
Study 28371872 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference ranges
Number of subjects: 501
Study 28371872 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil levels
Number of subjects: 501
Study 26253152 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal and multiannual cash transfers via mobile phones
Number of subjects: 0
Study 26253152 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cash transfers)
Number of subjects: 0
Study 23903014 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor stem cell infusion (DSCI)
Number of subjects: 9
Study 23903014 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DSCI)
Number of subjects: 9
Study 21913140 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate solution (3 ml · kg (‐1) body weight)
Number of subjects: 10
Study 21913140 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 10
Study 18312401 — intervention group
Group type: EXPERIMENTAL
Intervention: GW406381 (70 mg)
Number of subjects: 337
Study 18312401 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium (825 mg)
Number of subjects: 337
Study 18312401 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 337
Study 17060219 — intervention group
Group type: EXPERIMENTAL
Intervention: Two commonly used treatments for liquid aspiration
Number of subjects: 0
Study 12928123 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 176
Study 12928123 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GC)
Number of subjects: 176
Study 10666521 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine preemptively before surgery and maintained until skin closure
Number of subjects: 0
Study 10666521 — intervention group
Group type: COMPARATOR
Intervention: Saline control preemptively before surgery
Number of subjects: 0
Study 10666521 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine post-surgery via PCA pump
Number of subjects: 0
Study 9087009 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive dressing (OpSite Flexigrid)
Number of subjects: 8
Study 9087009 — intervention group
Group type: COMPARATOR
Intervention: Intact skin underneath the dressing
Number of subjects: 8
Study 7828490 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastroenterostomy
Number of subjects: 14
Study 7828490 — intervention group
Group type: COMPARATOR
Intervention: Billroth type-II gastroenterostomy
Number of subjects: 14
Study 7828490 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (both procedures)
Number of subjects: 14